semaglutide novo nordisk Ozempic® (semaglutide) GLP-1 RA for Type 2 Diabetes Novo Nordisk's semaglutide shows promise

Activation of OXGR1 by binding 2-oxoglutarate leads to the regulation of a signal transduction pathway involving signal transducer and activator of transcription-3 (STAT-3)

Follow us on social media for updates and exclusive offers

DISCLOSURES ABJ has received honoraria for speaking from Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Janssen, Merck, Novo Nordisk and Sanofi, and has been involved in advisory boards for Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk and Sanofi

Chicago Saha, Nidhi

The SURMOUNT-5 trial, published in The New England Journal of Medicine , directly compared tirzepatide to semaglutide and found tirzepatide produced 47% greater relative weight loss at 72 weeks, 20.2% of body weight versus 13.7%